| Date Filed | Type | Description |
| 10/06/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 10/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/27/2023 |
4
| Uihlein Richard E (10% Owner) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Exercised 1,466,204 warrants
@ $5, valued at
$7.3M
Exercised 170,000 warrants
@ $5, valued at
$850k
Exercised 200,000 warrants
@ $3, valued at
$600k
Exercised 200,000 warrants
@ $3.26, valued at
$652k
|
|
| 08/15/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 12,042 shares
@ $1.6, valued at
$19.3k
|
|
| 08/14/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/03/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 13,380 shares
@ $1.44, valued at
$19.3k
|
|
| 06/16/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 13,196 shares
@ $1.46, valued at
$19.3k
|
|
| 06/01/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 12,272 shares
@ $1.57, valued at
$19.3k
|
|
| 05/16/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 11,748 shares
@ $1.64, valued at
$19.3k
|
|
| 05/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 10,947 shares
@ $1.76, valued at
$19.3k
|
|
| 04/25/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/03/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 9,175 shares
@ $2.1, valued at
$19.3k
|
|
| 03/30/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 10,140 shares
@ $1.9, valued at
$19.3k
|
|
| 03/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/02/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 9,308 shares
@ $2.07, valued at
$19.3k
Paid exercise price by delivering 75,529 shares
@ $2.07, valued at
$156.3k
|
|
| 02/07/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 143,836 shares
@ $1.43, valued at
$205.7k
|
|
| 01/31/2023 |
4
| LEWIS JOEL (President and CEO) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 15,086 shares
@ $1.16, valued at
$17.5k
|
|
| 01/31/2023 |
5
| 10X Fund, L.P. (10% Owner) has filed a Form 5 on GALECTIN THERAPEUTICS INC |
| 01/30/2023 |
4
| Zordani Richard A. Jr. (Director) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 40,000 options to buy
@ $1.11, valued at
$44.4k
|
|
| 01/30/2023 |
4
| Shlevin Harold H. (Director) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 40,000 options to buy
@ $1.11, valued at
$44.4k
|
|
| 01/30/2023 |
4
| Schwartz Elissa J. (Director) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 40,000 options to buy
@ $1.11, valued at
$44.4k
|
|
| 01/30/2023 |
4
| Rubin Marc (Director) has filed a Form 4 on GALECTIN THERAPEUTICS INC|
Txns:
| Granted 40,000 options to buy
@ $1.11, valued at
$44.4k
|
|
|